That seems like an excellent angle to the issue - I agree that reference models and stakeholders' different attitudes towards them likely have a huge impact. As such, the criticisms the FDA faces might indeed be an issue! (at least that's how I understand your comment);
However, I'd carefully offer a bit of pushback on the aviation industry as an example, keeping in mind the difficult tradeoffs and diverging interests regulators will face in designing an approval process for AI systems. I think the problems that regulators will face are more similar to those of the FDA & policymakers (if you assume they are your audience) might be more comfortable with a model... (read 476 more words →)
That seems like an excellent angle to the issue - I agree that reference models and stakeholders' different attitudes towards them likely have a huge impact. As such, the criticisms the FDA faces might indeed be an issue! (at least that's how I understand your comment);
However, I'd carefully offer a bit of pushback on the aviation industry as an example, keeping in mind the difficult tradeoffs and diverging interests regulators will face in designing an approval process for AI systems. I think the problems that regulators will face are more similar to those of the FDA & policymakers (if you assume they are your audience) might be more comfortable with a model... (read 476 more words →)